Retrieve available abstracts of 106 articles: HTML format
Single Articles
June 2025
CAVALLARO G, Lazzarotto D, Pavoni C, Valsecchi F, et al Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute
lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913
protocol. A Campus ALL study.
Bone Marrow Transplant. 2025 Jun 2. doi: 10.1038/s41409-025-02632. PubMedAbstract available
May 2025
NAGLER A, Ferhat AT, Kayser S, Eder M, et al Prognostic significance of cytogenetic risk score in patients with secondary
acute myeloid leukemia undergoing allogeneic stem cell transplantation from
HLA-matched unrelated donors: a study from the ALWP /EBMT.
Bone Marrow Transplant. 2025 May 29. doi: 10.1038/s41409-025-02620. PubMedAbstract available
MOUKALLED N, Ferhat AT, Bazarbachi A, Blaise D, et al Improved outcomes over time in patients aged >/=60 years undergoing allogeneic
hematopoietic cell transplantation for acute lymphoblastic leukemia in first
complete remission: a large study by the EBMT acute leukemia working party.
Bone Marrow Transplant. 2025 May 28. doi: 10.1038/s41409-025-02630. PubMedAbstract available
ABDUL WAHID SF, Ismail NA, Md Fauzi MF, Mohd Idris MR, et al Clinical outcomes of a new local CD19 CAR-T cell therapy for patients with
relapsed or refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma in
Malaysia.
Bone Marrow Transplant. 2025 May 27. doi: 10.1038/s41409-025-02629. PubMed
KRAKOW EF, Lee N, Jenkins I, Sala-Torra O, et al A clinical solution for tracking clonal evolution of acute myeloid leukemia after
allogeneic transplantation using bulk next generation sequencing.
Bone Marrow Transplant. 2025 May 16. doi: 10.1038/s41409-025-02602. PubMedAbstract available
BATTIPAGLIA G, Labopin M, Kulagin A, Versluis J, et al Addition of mycophenolate mofetil to a calcineurin inhibitor and post-transplant
cyclophosphamide results in lower incidence of extensive chronic
graft-versus-host disease in HLA-matched allogeneic hematopoietic stem cell
transplantation for acute mye
Bone Marrow Transplant. 2025 May 13. doi: 10.1038/s41409-025-02610. PubMedAbstract available
April 2025
PERMINOVA M, Shelikhova L, Klimentova M, Skvortsova Y, et al Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD
after hematopoietic stem cells transplantation in children with acute leukemia:
results of a prospective trial.
Bone Marrow Transplant. 2025 Apr 25. doi: 10.1038/s41409-025-02566. PubMed
TARANTINO S, Labopin M, Zeiser R, Stelljes M, et al Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid
leukemia in active disease: a study from the Acute Leukemia Working Party of the
European Society for Blood and Marrow Transplantation.
Bone Marrow Transplant. 2025 Apr 23. doi: 10.1038/s41409-025-02596. PubMedAbstract available
BERGLAND BS, Remberger M, Tjonnfjord GE, Vo CD, et al Should a young matched unrelated donor be preferred over an older matched related
donor in allogeneic stem cell transplantation for acute leukemia and
myelodysplastic syndrome?
Bone Marrow Transplant. 2025 Apr 18. doi: 10.1038/s41409-025-02579. PubMed
GILLE AS, Lenez L, Vanhaesebrouck A, Rivet-Danon D, et al First-line chemotherapies administered before hematopoietic cell transplantation
in children with acute leukemia: effect on the spermatogonial pool.
Bone Marrow Transplant. 2025 Apr 17. doi: 10.1038/s41409-025-02547. PubMed
ABOU DALLE I, Labopin M, Khvedelidze I, Baron F, et al Growing adoption of pharmacologic maintenance therapy after allogeneic
hematopoietic cell transplantation in acute myeloid leukemia: a survey on behalf
of the EBMT acute leukemia working party.
Bone Marrow Transplant. 2025 Apr 15. doi: 10.1038/s41409-025-02576. PubMed
SENAPATI J, Garcia-Manero G, DiNardo CD, Deshmukh I, et al Barriers to allogeneic stem cell transplantation in responding patients with
TP53-mutated acute myeloid leukemia.
Bone Marrow Transplant. 2025 Apr 11. doi: 10.1038/s41409-025-02590. PubMed
ITONAGA H, Fukushima T, Kato K, Muranushi H, et al Bone marrow versus peripheral blood stem cells as the graft source for allogeneic
transplantation from HLA-matched relative donors in adult T-cell
leukemia/lymphoma: A nationwide retrospective study by the ATL working group of
the Japanese Society for
Bone Marrow Transplant. 2025 Apr 8. doi: 10.1038/s41409-025-02563. PubMed
LIU J, Li Y, Zhu F, Lv B, et al Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related
hematologic toxicity and prognosis in acute B-cell leukemia.
Bone Marrow Transplant. 2025 Apr 7. doi: 10.1038/s41409-025-02578. PubMed
SHIMIZU T, Arai Y, Kondo T, Yano S, et al Improved post-transplant outcomes for elderly acute myeloid leukemia patients
conditioned with FLU/BU4 rather than conventional MAC regimens.
Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02573. PubMedAbstract available
YANADA M, Yamasaki S, Hosoi H, Mizuno S, et al Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic
hematopoietic cell transplantation in acute myeloid leukemia.
Bone Marrow Transplant. 2025 Apr 5. doi: 10.1038/s41409-025-02585. PubMed
SPYRIDONIDIS A, Labopin M, Savani BP, Kulagin A, et al The impact of individual comorbidities in transplant recipients receiving
post-transplant cyclophosphamide.
Bone Marrow Transplant. 2025;60:499-506. PubMedAbstract available
VO PT, Sandmaier BM, Othus M, Ali N, et al Relationship between age, conditioning intensity, and outcome after allografting
in adults age >/=60 years with AML.
Bone Marrow Transplant. 2025;60:482-490. PubMedAbstract available
March 2025
STORCK TN, Morsink LM, Biswana A, Hazenberg CLE, et al Donor lymphocyte infusions after HLA-identical hematopoietic stem cell
transplantation with post-transplant cyclophosphamide in acute myeloid leukemia
patients.
Bone Marrow Transplant. 2025 Mar 19. doi: 10.1038/s41409-025-02552. PubMed
CALVO C, Mornet C, Storey C, Halfon-Domenech C, et al Adult height and growth hormone therapy in childhood acute lymphoblastic leukemia
survivors treated with total body irradiation and hematopoietic stem cell
transplantation before puberty.
Bone Marrow Transplant. 2025 Mar 3. doi: 10.1038/s41409-025-02532. PubMed
ZHOU JY, Chen YX, Yuan HL, Xu YJ, et al A multifactorial risk scoring system for the prediction of early relapse in CMML
patients with allo-HSCT: a nationwide representative multicenter study.
Bone Marrow Transplant. 2025;60:310-318. PubMedAbstract available
February 2025
GANG M, Othus M, Sandmaier BM, Davis C, et al Modulators of relapse risk in adults allografted for acute myeloid leukemia in
measurable residual disease-positive remission.
Bone Marrow Transplant. 2025 Feb 17. doi: 10.1038/s41409-025-02533. PubMed
SANZ J, Labopin M, Versluis J, Blaise D, et al Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid
leukemia patients undergoing stem cell transplantation with post-transplant
cyclophosphamide: a study from the acute leukemia working party of the EBMT.
Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02527. PubMedAbstract available
ZHOU J, Wang F, Yang S, Zhang Y, et al Survival outcomes between haploidentical stem cell transplantation and
chemotherapy for blastic plasmacytoid dendritic cell neoplasm.
Bone Marrow Transplant. 2025 Feb 12. doi: 10.1038/s41409-025-02528. PubMedAbstract available
SHAFFER BC, Kebriaei P, de Lima M, Jimenez Jimenez AM, et al Measurable residual disease testing and allogeneic hematopoietic cell
transplantation for AML: adapting Pre-MEASURE to clinical practice.
Bone Marrow Transplant. 2025;60:128-134. PubMedAbstract available
GOMEZ-ARTEAGA A, Chokr N, Auletta JJ Precision medicine results from equitable representation.
Bone Marrow Transplant. 2025;60:122-127. PubMedAbstract available
January 2025
NEUPANE B, Ventura K, Parr K, Lee JR, et al Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia
neoantigens elicit immune responses in transplant recipients?
Bone Marrow Transplant. 2025 Jan 29. doi: 10.1038/s41409-025-02515. PubMed
OSHIMA S, Arai Y, Kondo T, Yano S, et al Myeloablative conditioning in cord blood transplantation for acute myeloid
leukemia patients is efficacious only until age 55.
Bone Marrow Transplant. 2025 Jan 21. doi: 10.1038/s41409-025-02508. PubMedAbstract available
BLACKMON AL, Grunwald MR Editorial: Molecular MRD testing in patients with acute myeloid leukemia.
Bone Marrow Transplant. 2025 Jan 11. doi: 10.1038/s41409-024-02493. PubMed
December 2024
YU F, Niu J, Yang J, Hou J, et al Optimal timing and impact of allogeneic peripheral blood stem cell
transplantation in adult T-cell lymphoblastic lymphoma: insights from a large
cohort multi-center real-world study in Shanghai.
Bone Marrow Transplant. 2024 Dec 20. doi: 10.1038/s41409-024-02500. PubMedAbstract available
DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU
(FBM110) in patients with relapsed/refractory AML undergoing allogeneic
hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute
Leukemia Working Part
Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499. PubMedAbstract available
BLACKMON A, Afkhami M, Yang D, Mokhtari S, et al Fludarabine melphalan reduced intensity conditioning vs radiation-based
myeloablative conditioning in patients undergoing allogeneic transplantation for
acute myeloid leukemia with measurable residual disease.
Bone Marrow Transplant. 2024 Dec 18. doi: 10.1038/s41409-024-02491. PubMedAbstract available
WANG MM, Huang SM, Huang YH, Zhang J, et al Quantification of the FLT3 internal tandem duplication is a reliable marker for
monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD
mutations.
Bone Marrow Transplant. 2024 Dec 10. doi: 10.1038/s41409-024-02495. PubMed
SUN J, Zhang YC, Wei J, Xu YJ, et al Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive
chemotherapy in patients with myeloid sarcoma: a nationwide representative
multicenter study.
Bone Marrow Transplant. 2024 Dec 2. doi: 10.1038/s41409-024-02485. PubMedAbstract available
SALAS MQ, Cascos E, Lopez-Garcia A, Perez-Lopez E, et al Cardiac events occurring after allogeneic hematopoietic cell transplantation with
post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC.
Bone Marrow Transplant. 2024;59:1694-1703. PubMedAbstract available
BRUNE M, Kiss T, Anderson H, Nicklasson M, et al Reduced Intensity transplantation vs chemotherapy in CR1. A prospective,
pseudorandomized study in 50-70 year old AML patients.
Bone Marrow Transplant. 2024;59:1676-1682. PubMedAbstract available
November 2024
MOLINOS-QUINTANA A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, et al Successful allogeneic CD34(+) hematopoietic stem cell boost for prolonged
cytopenias following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
On behalf of the Spanish Group for Hematopoietic Transplantation and Cellular
Therapy (GETH-TC).
Bone Marrow Transplant. 2024 Nov 17. doi: 10.1038/s41409-024-02473. PubMed
LI SQ, Yu CZ, Xu LP, Wang Y, et al Pretransplantation risk factors for positive MRD after allogeneic stem cell
transplantation in AML patients: a prospective study.
Bone Marrow Transplant. 2024 Nov 16. doi: 10.1038/s41409-024-02466. PubMedAbstract available
CHRISTOPHER MR, Nawas MT, Reagan JL Molecular measurable residual disease monitoring and transplant indications in
NPM1 mutated acute myeloid leukemia.
Bone Marrow Transplant. 2024 Nov 13. doi: 10.1038/s41409-024-02465. PubMedAbstract available
GUI G, Ravindra N, Hegde PS, Andrew G, et al Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid
leukemia.
Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02447. PubMedAbstract available
MA R, Liao Y, Zhang XH, Xu LP, et al Pre-transplant disease burden rather than age or donor type was associated with
survival of hematopoietic cell transplantation for elderly patients with acute
myeloid leukemia.
Bone Marrow Transplant. 2024 Nov 6. doi: 10.1038/s41409-024-02457. PubMed
OTOUKESH S, Yang D, Mokhtari S, Pourhassan H, et al Comparing transplant outcomes in ALL patients after myeloablative conditioning in
mismatch-related or unrelated donor settings.
Bone Marrow Transplant. 2024;59:1542-1551. PubMedAbstract available
October 2024
ELGHAWY O, Deshpande S, Sussman J, Garfall A, et al Characteristics and outcomes of therapy-related acute leukemia following
autologous transplant (Auto-HCT) for multiple myeloma.
Bone Marrow Transplant. 2024 Oct 30. doi: 10.1038/s41409-024-02455. PubMedAbstract available
GUI G, Ravindra N, Hegde PS, Andrew G, et al Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid
leukemia.
Bone Marrow Transplant. 2024 Oct 25. doi: 10.1038/s41409-024-02449. PubMedAbstract available
HEGDE PS, Andrew G, Gui G, Ravindra N, et al Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic
transplant for acute myeloid leukemia.
Bone Marrow Transplant. 2024 Oct 18. doi: 10.1038/s41409-024-02444. PubMed
NGO D, Blackmon A, Al Malki MM Dasatinib maintenance following allogeneic transplantation in acute myeloid
leukemia with KIT mutation.
Bone Marrow Transplant. 2024 Oct 8. doi: 10.1038/s41409-024-02425. PubMed
August 2024
OTHUS M, Baccon D, Ali N, Rodriguez-Arboli E, et al Relationship between morphologic remission with or without hematologic recovery
and outcome after allogeneic hematopoietic cell transplantation in adult acute
myeloid leukemia.
Bone Marrow Transplant. 2024 Aug 29. doi: 10.1038/s41409-024-02407. PubMedAbstract available
ZHANG H, Guo W, Wang J, Lu N, et al Impact of bone marrow fibrosis on outcomes of allogeneic hematopoietic stem cell
transplantation in acute myeloid leukemia.
Bone Marrow Transplant. 2024 Aug 27. doi: 10.1038/s41409-024-02402. PubMedAbstract available
SAKAGUCHI H, Taga T, Ishida H, Hama A, et al Salvage hematopoietic cell transplantation for children with acute myeloid
leukemia relapsed after first transplantation: a Japanese national registry
study.
Bone Marrow Transplant. 2024 Aug 22. doi: 10.1038/s41409-024-02396. PubMed
NAGLER A, Labopin M, Salmenniemi U, Wu D, et al Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in
first remission: a longitudinal study of >15 years from the ALWP of the EBMT.
Bone Marrow Transplant. 2024 Aug 20. doi: 10.1038/s41409-024-02379. PubMedAbstract available
NAGLER A, Labopin M, Swoboda R, Blaise D, et al Young (<35 years) haploidentical versus old (>/=35 years) mismatched unrelated
donors and vice versa for allogeneic stem cell transplantation with
post-transplant cyclophosphamide in patients with acute myeloid leukemia in first
remission: a study on
Bone Marrow Transplant. 2024 Aug 18. doi: 10.1038/s41409-024-02400. PubMedAbstract available
MOHTY R, Bazarbachi AH, Labopin M, Esteve J, et al Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in
patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell
transplantation: a study of the ALWP of the EBMT.
Bone Marrow Transplant. 2024 Aug 14. doi: 10.1038/s41409-024-02384. PubMedAbstract available
GALLI E, Corrente A, Chiusolo P, Sica S, et al CAR-T treatment is safe and effective in adult patients with Down syndrome and
B-cell acute lymphoblastic leukemia (B-ALL).
Bone Marrow Transplant. 2024 Aug 9. doi: 10.1038/s41409-024-02386. PubMed
AL HAMED R, Labopin M, Wu D, Gedde-Dahl T, et al Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid
leukemia in first complete remission: data from the EBMT.
Bone Marrow Transplant. 2024 Aug 2. doi: 10.1038/s41409-024-02373. PubMedAbstract available
July 2024
GANZEL C, Wang Y, Roopcharan K, Sun Z, et al Correction: Shorter long-term post-transplant life expectancy may be due to prior
chemotherapy for the underlying disease: analysis of 3012 patients with acute
myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
Bone Marrow Transplant. 2024 Jul 18. doi: 10.1038/s41409-024-02337. PubMed
AHN J, Yoon JH, Kwag D, Min GJ, et al Comparative analysis of reduced toxicity conditioning regimens between
fludarabine plus melphalan and fludarabine plus busulfex in adult patients with
acute lymphoblastic leukemia.
Bone Marrow Transplant. 2024 Jul 12. doi: 10.1038/s41409-024-02363. PubMedAbstract available
BUG G, Labopin M, Kulagin A, Blaise D, et al Tacrolimus versus cyclosporine a combined with post-transplantation
cyclophosphamide for AML In first complete remission: a study from the acute
leukemia working party (EBMT).
Bone Marrow Transplant. 2024 Jul 3. doi: 10.1038/s41409-024-02331. PubMedAbstract available
June 2024
ZHU J, Xu M, Ye Y, Ru Y, et al Haploidentical-cord blood stem cell transplantation versus haploidentical stem
cell transplantation for non-CR acute leukemia patients: a multicenter study.
Bone Marrow Transplant. 2024 Jun 19. doi: 10.1038/s41409-024-02335. PubMed
STEINER N, Massoud R, Klyuchnikov E, Gagelmann N, et al Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as
GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
Bone Marrow Transplant. 2024 Jun 14. doi: 10.1038/s41409-024-02328. PubMedAbstract available
ORCHARD K, Langford J, Guy M, Lewis G, et al Efficient bone marrow irradiation and low uptake by non-haematological organs
with an yttrium-90-anti-CD66 antibody prior to haematopoietic stem cell
transplantation.
Bone Marrow Transplant. 2024 Jun 12. doi: 10.1038/s41409-024-02317. PubMedAbstract available
EL CHEIKH J, Ngoya M, Galimard JE, Remenyi P, et al Prognostic factors impacting post-transplant outcomes in adult T-cell acute
lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working
party.
Bone Marrow Transplant. 2024 Jun 4. doi: 10.1038/s41409-024-02300. PubMedAbstract available
KUROSAWA S, Shimomura Y, Ishiyama K, Fuse K, et al Updated comparable efficacy of cord blood transplantation for chronic
myelomonocytic leukaemia: a nationwide study.
Bone Marrow Transplant. 2024;59:742-750. PubMedAbstract available
May 2024
GANZEL C, Yating W, Roopcharan K, Sun Z, et al Shorter long-term post-transplant life expectancy may be due to prior
chemotherapy for the underlying disease: analysis of 3012 patients with acute
myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02308. PubMedAbstract available
TOLOSA-RIDAO C, Suarez-Lledo M, Jimenez-Vicente C, Cortes-Bullich A, et al Allogeneic hematopoietic cell transplantation with sequential conditioning
regimen in relapsed refractory acute myeloid leukemia.
Bone Marrow Transplant. 2024 May 22. doi: 10.1038/s41409-024-02310. PubMed
HU X, Wang Z, Qin Y, Xu J, et al Allogeneic haematopoietic stem cell transplantation might overcome the poor
prognosis of adolescents and adult patients with T-lineage acute lymphoblastic
leukaemia and CDKN2 deletion.
Bone Marrow Transplant. 2024 May 20. doi: 10.1038/s41409-024-02306. PubMedAbstract available
MORA E, Montoro J, Balaguer A, Rovira M, et al Total body irradiation versus thiotepa/busulfan-based conditioning regimens for
myeloablative allogeneic stem cell transplantation in adults with acute
lymphoblastic leukemia.
Bone Marrow Transplant. 2024 May 16. doi: 10.1038/s41409-024-02298. PubMedAbstract available
SINANIDIS I, Hochman MJ, Tsai HL, Randall MP, et al Favorable outcomes in MDS and oligoblastic AML-MR after reduced-intensity
conditioning allogeneic bone marrow transplantation with post-transplantation
cyclophosphamide.
Bone Marrow Transplant. 2024 May 7. doi: 10.1038/s41409-024-02299. PubMed
BERNING P, Kolloch L, Reicherts C, Call S, et al Comparable outcomes for TBI-based versus treosulfan based conditioning prior to
allogeneic hematopoietic stem cell transplantation in AML and MDS patients.
Bone Marrow Transplant. 2024 May 3. doi: 10.1038/s41409-024-02295. PubMedAbstract available
BEELEN DW, Iacobelli S, Koster L, Eikema DJ, et al Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide
conditioning in older AML or MDS patients - A clinical trial to registry data
comparison.
Bone Marrow Transplant. 2024;59:670-679. PubMedAbstract available
April 2024
NAGLER A, Labopin M, Swoboda R, Schroeder T, et al Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate
mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and
methotrexate combinations as graft-versus-host disease prophylaxis post
allogeneic stem cell transplanta
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02284. PubMedAbstract available
DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al Safety and efficacy of a new academic CD19-directed CAR-T cell for
refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in
Brazil.
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283. PubMed
SHEN Y, Liu M, Shen D, Chu M, et al Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide
for allogeneic hematopoietic stem cell transplantation in patients with acute T
lymphoblastic leukemia: a large-scale propensity score matching-based study.
Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02280. PubMed
FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al Outcomes of haploidentical bone marrow transplantation in infant acute leukemia:
a single center experience.
Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281. PubMed
BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al EASIX and CPSS Cytogenetics score-based composite risk model for patients with
CMML undergoing allogeneic transplant.
Bone Marrow Transplant. 2024;59:558-560. PubMed
March 2024
MAFFINI E, Labopin M, Kroger N, Finke J, et al Allogeneic hematopoietic cell transplantation for older patients with AML with
active disease. A study from the Acute Leukemia Working Party of the European
Society for Blood and Marrow Transplantation (EBMT).
Bone Marrow Transplant. 2024 Mar 30. doi: 10.1038/s41409-024-02275. PubMedAbstract available
KOO RM, Wong E, Davis JE, Perera T, et al A phase 1 dose-escalation study of low-dose lenalidomide maintenance
post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia
or myelodysplastic syndrome.
Bone Marrow Transplant. 2024 Mar 27. doi: 10.1038/s41409-023-02195. PubMed
SHANG Q, Bai L, Cheng Y, Suo P, et al Outcomes and prognosis of haploidentical haematopoietic stem cell transplantation
in children with FLT3-ITD mutated acute myeloid leukaemia.
Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02214. PubMedAbstract available
PARK S, Bang SY, Kwag D, Lee JH, et al Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute
myeloid leukemia patients who received first allogeneic hematopoietic stem cell
transplantation in measurable residual disease-negative CR1.
Bone Marrow Transplant. 2024 Mar 4. doi: 10.1038/s41409-024-02255. PubMedAbstract available
February 2024
HIROSE A, Koh H, Nakamae M, Nakashima Y, et al A comparison of long-term outcomes by donor type in the era of
post-transplantation cyclophosphamide for aggressive adult T-cell
leukemia/lymphoma.
Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231. PubMed
YANADA M, Yano S, Kuwatsuka Y, Kawamura K, et al The effect of center experience on allogeneic hematopoietic cell transplantation
outcomes in acute myeloid leukemia.
Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02222. PubMedAbstract available
SPYRIDONIDIS A, Labopin M, Gedde-Dahl T, Ganser A, et al Validation of the transplant conditioning intensity (TCI) index for allogeneic
hematopoietic cell transplantation.
Bone Marrow Transplant. 2024;59:217-223. PubMedAbstract available
January 2024
XIAO M, Zhou J, Zhu X, He Y, et al A prognostic score system in adult T-cell acute lymphoblastic leukemia after
hematopoietic stem cell transplantation.
Bone Marrow Transplant. 2024 Jan 24. doi: 10.1038/s41409-024-02211. PubMedAbstract available
CHEN W, Shi J, Luo Y, Yu J, et al Selective histone deacetylase inhibitor after allo-HCT for T-cell acute
lymphoblastic leukemia or T-cell lymphoma.
Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191. PubMed
ALBINGER N, Muller S, Kostyra J, Kuska J, et al Manufacturing of primary CAR-NK cells in an automated system for the treatment of
acute myeloid leukemia.
Bone Marrow Transplant. 2024 Jan 22. doi: 10.1038/s41409-023-02180. PubMedAbstract available
SHARMA A, Galimard JE, Pryce A, Bhoopalan SV, et al Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem
cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study.
Bone Marrow Transplant. 2024 Jan 15. doi: 10.1038/s41409-024-02197. PubMedAbstract available
VELARDI A, Mancusi A, Ruggeri L, Pierini A, et al How adoptive transfer of components of the donor immune system boosts GvL and
prevents GvHD in HLA-haploidentical hematopoietic transplantation for acute
leukemia.
Bone Marrow Transplant. 2024 Jan 11. doi: 10.1038/s41409-024-02199. PubMedAbstract available
ARCURI LJ Re: Prophylactic versus preemptive modified donor lymphocyte infusion for
high-risk acute leukemia after allogeneic hematopoietic stem cell
transplantation: a multicenter retrospective study.
Bone Marrow Transplant. 2024 Jan 10. doi: 10.1038/s41409-023-02186. PubMed
SADOWSKA-KLASA A, Zaucha JM, Labopin M, Bourhis JH, et al Allogeneic hematopoietic cell transplantation is equally effective in secondary
acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT
registry.
Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02192. PubMedAbstract available
NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al Allogeneic haematopoietic cell transplantation for therapy-related myeloid
neoplasms arising following treatment for lymphoma: a retrospective study on
behalf of the Chronic Malignancies Working Party of the EBMT.
Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193. PubMedAbstract available
RAVINDRA N, Dillon LW, Gui G, Smith M, et al Persistent IDH mutations are not associated with increased relapse or death in
patients with IDH-mutated acute myeloid leukemia undergoing allogeneic
hematopoietic cell transplant with post-transplant cyclophosphamide.
Bone Marrow Transplant. 2024 Jan 5. doi: 10.1038/s41409-023-02189. PubMed
December 2023
ZHANG X, Pang Y, Wei C, Liang D, et al Role of allogeneic hematopoietic stem cell transplantation in patients with
high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical
outcomes.
Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182. PubMed
EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR
T-cell therapy.
Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176. PubMedAbstract available
POIRE X, Labopin M, Polge E, Ganser A, et al Allogeneic hematopoietic cell transplantation for acute myeloid leukemia with
hyperdiploid complex karyotype.
Bone Marrow Transplant. 2023 Dec 13. doi: 10.1038/s41409-023-02167. PubMedAbstract available
DUQUE-AFONSO J, Finke J, Ngoya M, Galimard JE, et al Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or
thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing
allogeneic hematopoietic stem cell transplantation - a registry study on behalf
of the EBMT
Bone Marrow Transplant. 2023 Dec 2. doi: 10.1038/s41409-023-02150. PubMedAbstract available
November 2023
CAO LQ, Huo WX, Zhang XH, Xu LP, et al Peripheral blood stem cell transplantation from haploidentical related donor
could achieve satisfactory clinical outcomes for intermediate- or high-risk adult
acute myeloid leukemia patients.
Bone Marrow Transplant. 2023 Nov 15. doi: 10.1038/s41409-023-02117. PubMedAbstract available
HARBI S, Brac de la Perriere L, Bouchacourt B, Garciaz S, et al Peripheral blood haploidentical hematopoietic cell transplantation for patients
aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic
syndrome.
Bone Marrow Transplant. 2023 Nov 3. doi: 10.1038/s41409-023-02134. PubMedAbstract available
October 2023
YANG L, Lai X, Yang T, Lu Y, et al Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk
acute leukemia after allogeneic hematopoietic stem cell transplantation: a
multicenter retrospective study.
Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02137. PubMedAbstract available
HUANG J, Feng B, Cheng Y, Xu L, et al Unmanipulated haploidentical hematopoietic stem cell transplantation for mixed
phenotype acute leukemia: a single center study.
Bone Marrow Transplant. 2023 Oct 31. doi: 10.1038/s41409-023-02141. PubMed
CANCIO M, Troullioud Lucas AG, Bierings M, Klein E, et al Predictors of outcomes in hematopoietic cell transplantation for Fanconi anemia.
Bone Marrow Transplant. 2023 Oct 17. doi: 10.1038/s41409-023-02121. PubMedAbstract available
CHO C, Devlin S, Maloy M, Horowitz MM, et al Application of the CIBMTR One Year Survival Outcomes Calculator as a tool for
retrospective analysis.
Bone Marrow Transplant. 2023;58:1089-1095. PubMedAbstract available
September 2023
SATTY AM, Klein E, Mauguen A, Kunvarjee B, et al T-cell depleted allogeneic hematopoietic stem cell transplant for the treatment
of Fanconi anemia and MDS/AML.
Bone Marrow Transplant. 2023 Sep 29. doi: 10.1038/s41409-023-02113. PubMedAbstract available
CAO Y, Zhang C, Zhao X, Huang J, et al Allogeneic hematopoietic stem cell transplantation for adult acute myeloid
leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world
study in China.
Bone Marrow Transplant. 2023 Sep 20. doi: 10.1038/s41409-023-02106. PubMed
HARADA N, Okamura H, Makuuchi Y, Kuno M, et al Third HLA-haploidentical stem cell transplantation using post-transplant
cyclophosphamide for relapsed acute leukemia.
Bone Marrow Transplant. 2023 Sep 15. doi: 10.1038/s41409-023-02108. PubMed
NAGLER A, Labopin M, Kroger N, Schroeder T, et al The role of anti-thymocyte globulin in allogeneic stem cell transplantation
(HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a
study from the ALWP /EBMT.
Bone Marrow Transplant. 2023 Sep 2. doi: 10.1038/s41409-023-02095. PubMedAbstract available
JENG MY, Kong D, Rajalingam R, Lin RJ, et al Lack of disease control remains a major barrier to transplant for older patients
with AML.
Bone Marrow Transplant. 2023;58:1054-1056. PubMed
August 2023
REY G, Daguenet E, Bonjean P, Devillier R, et al Allogeneic hematopoietic stem cell transplantation for adults with
therapy-related acute myeloid leukaemia: a retrospective multicentre study on
behalf of the SFGM-TC.
Bone Marrow Transplant. 2023 Aug 31. doi: 10.1038/s41409-023-02082. PubMedAbstract available